Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of SPOT-mRNA01 in Healthy Adults
NCT06567119Phase 1Not yet recruiting
- Sponsor
- Haining Sipo Biotech
- Start
- Jan 2027
- Primary completion
- Jan 2029
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 1, randomised, double-blind trial in Skin aging comparing SPOT-mRNA01 with Placebo (2 arms). Primary endpoint: Adverse Events at 3 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
SPOT-mRNA01
03
Conditions
Skin aging
Beyond the preview
Go deeper on NCT06567119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567119.